NEWS | BEAM Alliance


MaaT Pharma Expands Patent Portfolio with Three Granted Patents Covering its Microbiome Restoration Biotherapeutic Platform

Lyon, France, May 22, 2019 – MaaT Pharma announced today that the Institut National de la Propriété Industrielle (INPI), the French Patent Office, has issued three new patents to the company covering its sample collection device and the overall processes associated with obtaining, processing, storing and administering human gut samples, ensuring that the highest quality of microbiota is present in MaaT Pharma’s biologic drugs. In addition, the patents cover an innovative process to freeze-dry samples preserving the viability and taxonomic profile of the microbiome and enabling the development of an oral formulation. These patented processes developed under a five year research collaboration with the French National Institute for Agricultural Research (INRA) are a fundamental part of MaaT Pharma’s integrated Microbiome Restoration Biotherapeutic (MMRB) platform and have a broad applicability in treating dysbiosis-related diseases.

Full PR available here